Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Triferic (ferric pyrophosphate citrate) is a water-soluble iron salt used to maintain iron levels in adult patients with chronic kidney disease (CKD) on hemodialysis. Unlike traditional intravenous (IV) iron formulations that are administered intermittently, Triferic is added to the dialysate and delivers iron directly to transferrin as blood passes through the dialyzer. It is indicated for the replacement of ongoing iron loss and maintenance of hemoglobin levels in patients receiving hemodialysis, without increasing iron stores. Triferic supports erythropoiesis and can be used concomitantly with erythropoiesis-stimulating agents (ESAs).
Fact Table | |
Formula | Fe5O6(C6H6O7)5(P2O7)3 |
License | US FDA (2015) |
Bioavailability | 100% (via dialysate); ~90% (IV) |
Legal status | Prescription only |
Chemical Name | Ferric Pyrophosphate Citrate |
Elimination half-life | ~1.5 hours (plasma iron) |
Dosage (Strength) | 27.2 mg iron/2 mL vial (IV); 50 mg iron/5 mL ampule (dialysate) |
Pregnancy | Use if clearly needed; no human data |
Brands | Triferic, Triferic AVNU |
Protein binding | Binds to transferrin in plasma |
PubChem CID | 71587661 |
MedlinePlus | a620026 |
ChEBI | N/A |
ATC code | B03AB10 |
DrugBank | DB15292 |
KEGG | D10966 |
Routes of administration | Intravenous (IV), Dialysate (hemodialysis) |
Triferic is administered during each hemodialysis session via the dialysate. The recommended dose is 27.2 mg of iron per hemodialysis treatment, typically provided through a 5 mL ampule of Triferic diluted into 2.5 gallons (9.46 L) of bicarbonate concentrate. The solution is prepared prior to dialysis according to standard bicarbonate mixing procedures. The product should not be administered intravenously. Triferic must be used only with hemodialysis systems that allow for iron delivery via dialysate.
Each 5 mL ampule of Triferic contains:
Triferic is a clear, colorless to pale yellow solution that is preservative-free and intended for single use only.
Triferic is contraindicated in patients with:
Triferic is not intended for use as a treatment for iron deficiency anemia outside the hemodialysis setting. It should not be used in patients not receiving hemodialysis or as a substitute for intravenous iron when repletion of iron stores is required. Iron parameters such as serum ferritin and transferrin saturation should be monitored regularly. Use caution in patients with ongoing inflammatory conditions that may influence iron metabolism. There is limited data on use in pregnant or lactating women, and the risk to the fetus or infant cannot be excluded.
Triferic is generally well tolerated. Reported side effects may include: